Based on the progress and results obtained in the first nine months of 2024, BioPorto maintains its financial guidance for 2024, as most recently described in its Interim Report for the Second Quarter ...
The company offers genomics products through its subsidiaries, Integrated DNA Technologies, Inc., Cepheid, Inc., and Beckman Coulter, which operates under the Life Sciences and Diagnostics segments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback